Stiefel, a GSK Company
Stiefel, a GSK Company sponsors 37 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 37 completed. 22 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 6 trials.
Trial Pipeline
37 total, page 1 of 1
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
NCT02673619
A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream
NCT02411162
A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects
NCT01984775
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne
NCT01446237
Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.
NCT01323673
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
NCT01119651
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
NCT01139580
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
NCT01115322
A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers
NCT01114841
A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers
NCT01112787
A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule
NCT01039883
A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
NCT01019603
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne
NCT01017120
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301
NCT01017146
A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus
NCT01014962
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
NCT01015638
Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications
NCT00964366
A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
NCT00964223
Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications
NCT00926367
A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash
NCT00891982
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
NCT00852540
A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis
NCT00852761
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
NCT00817063
Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne
NCT00776919
Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis
NCT00828464
Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis
NCT00730405
Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne
NCT00713609
Study to Assess Blood Levels of Itraconazole During a Two-Week Period
NCT00695071
A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
NCT00689117
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies
NCT00689481
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies
NCT00688519
Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam
NCT00842153
Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne
NCT00837213
Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne
NCT00841776
A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)
NCT00509275
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
NCT00702507
Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.
NCT00356915
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 3 |
| Phase 3 | 11 |
| Phase 4 | 11 |
Therapeutic Areas
What the Pipeline for Stiefel, a GSK Company Shows
According to the ClinicalTrials.gov registry, Stiefel, a GSK Company is linked to 37 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 37 are already marked complete, representing roughly 100% of the total.
The phase mix for Stiefel, a GSK Company reports 22 late-stage studies (Phase 3 and Phase 4 combined) and 14 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Stiefel, a GSK Company is Acne Vulgaris with 6 linked trials, and 4 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.